Page 32 - Anjali Singh

Read all the latest news, articles and videos by Anjali Singh on the recent topics, trending and viral stories and top news headlines at Business Standard.
Medindia

Newly FDA-Approved GSK's Exdensur Offers Hope for Severe Asthma

What is Exdensur? A new FDA-approved asthma biologic from GSK that only needs two doses a year for severe eosinophilic asthma ...

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...

FDA approves Exdensur for severe asthma

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...
Medical Dialogues

FDA Approves Depemokimab-ulaa as First Twice-Yearly Biologic for Severe Eosinophilic Asthma

Depemokimab-ulaa (Exdensur) has been approved by the US FDA as add-on maintenance therapy for severe asthma with an ...
Healio

FDA approves depemokimab for severe eosinophilic asthma

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...
Medscape

FDA Approves Add-On Depemokimab for Severe Asthma

The US FDA has approved depemokimab as an add-on maintenance therapy for individuals aged 12 years or older with severe asthma, according to a press release from manufacturer GlaxoSmithKline.